Overview

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Ritonavir
Tipranavir